There were 1,832 press releases posted in the last 24 hours and 426,412 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image